Search
for
Sort by
Research 31–60 of 163
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- Pharmacological Treatment of Alopecia
- Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
- A Porcine Model for the Development and Testing of Preoperative Skin Preparations
- Comprehension Testing for OTC Drug Labels: Goals, Methods, Target Population, and Testing Environment
- Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study
- Drug-Induced Hair Loss and Hair Growth
- Women's midlife health Reframing menopause
- Systematic review of platelet‐rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability
- Systemic causes of hair loss
- Qualidade de vida relacionada à saúde em homens e mulheres com alopecia androgenética em uso de terapia com luz de baixa intensidade
- What does the research say about androgen use and cerebrovascular events?
- Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Protective and Restorative Effects of a Bio-Based Crosslinking Complex on Chemically Damaged Hair
- Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis
- Effective holistic characterization of small molecule effects using heterogeneous biological networks
- Protein Immobilization on Bacterial Cellulose for Biomedical Application
- Microalgal Biofactories: Sustainable Solutions for Nutrition and Cosmetics
- Clinical Use of Extracellular Vesicles in the Management of Male and Female Pattern Hair Loss: A Preliminary Retrospective Institutional Review Board Safety and Efficacy Study
- Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
- FDA declines approval of testosterone drug for third time
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Novel acne cream seeks FDA approval
- FDA declines approval of testosterone drug for third time
- Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024